Sunshine Lake Pharma (6887) Stock Overview

Engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. More details

6887 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	2/6
Financial Health	5/6
Dividends	0/6

Risk Analysis

Profit margins (13%) are lower than last year (31.7%)

6887 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Sunshine Lake Pharma Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Sunshine Lake Pharma
Historical stock prices
Current Share Price	HK$48.00
52 Week High	HK$67.30
52 Week Low	HK$32.62
Beta	0.018
1 Month Change	-1.19%
3 Month Change	-20.32%
1 Year Change	39.82%
3 Year Change	157.71%
5 Year Change	30.18%
Change since IPO	74.05%

Recent updates

Shareholder Returns

	6887	HK Pharmaceuticals	HK Market
7D	3.3%	1.1%	-1.3%
1Y	39.8%	58.2%	29.6%

Return vs Industry: 6887 underperformed the Hong Kong Pharmaceuticals industry which returned 58.2% over the past year.

Return vs Market: 6887 exceeded the Hong Kong Market which returned 29.6% over the past year.

Price Volatility

Is 6887's price volatile compared to industry and market?
6887 volatility
6887 Average Weekly Movement	6.5%
Pharmaceuticals Industry Average Movement	6.3%
Market Average Movement	7.1%
10% most volatile stocks in HK Market	15.1%
10% least volatile stocks in HK Market	3.3%

Stable Share Price: 6887 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 6887's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2001	4,861	Wenjia Li	www.hecpharm.com

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients. The company also engages in the wholesale, retail, import, and export of drugs.

Sunshine Lake Pharma Co., Ltd. Fundamentals Summary

How do Sunshine Lake Pharma's earnings and revenue compare to its market cap?
6887 fundamental statistics
Market cap	HK$27.68b
Earnings (TTM)	HK$526.93m
Revenue (TTM)	HK$4.06b

52.5x

P/E Ratio

6.8x

P/S Ratio

Is 6887 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6887 income statement (TTM)
Revenue	CN¥3.72b
Cost of Revenue	CN¥929.73m
Gross Profit	CN¥2.79b
Other Expenses	CN¥2.31b
Earnings	CN¥482.71m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.84
Gross Margin	75.03%
Net Profit Margin	12.96%
Debt/Equity Ratio	22.6%

How did 6887 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/03 00:46
End of Day Share Price	2025/11/03 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sunshine Lake Pharma Co., Ltd. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ling Zhang	China Merchants Securities (HK) Co., Ltd
null null	CMB International Securities Limited
Xiao Wei Lin	Everbright Securities Co. Ltd.

Sunshine Lake Pharma Co., Ltd.SEHK:6887 Stock Report